teal triangle graphic

Alkermes Pathways Research Awards®

About Pathways


With millions of people impacted by neurological disorders, more research is urgently needed to advance science in this area. The Alkermes Pathways Research Awards® program is designed to support the next generation of researchers who are working on the front lines to advance our understanding of diseases in the field of neuroscience.

The Alkermes Pathways Research Awards® program provides opportunities for individual grants of up to $100,000 per research project for early-career investigators focused on research relating to schizophrenia, bipolar disorder, alcohol use disorder (AUD) or opioid use disorder (OUD).

Previous Pathways awardees

Schizophrenia & Bipolar Disorder Areas of Interest

  • Preclinical, clinical, translational and epidemiological research
  • Research on treatment and patient- centered outcomes
  • Clinical and health economic outcomes using real-world data
  • Outcomes research supporting continuity of care utilizing telehealth or other technology-based approaches

AUD & OUD Disorder Areas of Interest

  • Clinical, translational and epidemiological research*
  • Research on treatment and patient- centered outcomes
  • Clinical and health economic outcomes using real-world data
  • Outcomes research supporting continuity of care utilizing telehealth or other technology-based approaches
*Please note that we are not accepting preclinical applications for the 4th annual application cycle for AUD or OUD grants.

General Eligibility Criteria

The Alkermes Pathways Research Awards® program is for investigators who are in the early stages of their career. Research grants will be awarded to applicants who focus on and have demonstrated a commitment to schizophrenia, bipolar disorder, AUD or OUD research.

To be eligible, an applicant must meet the following criteria:

  • Has an M.D., Ph.D., or equivalent
  • Is affiliated with a medical or research center within the United States at the time of application
  • Is within 5 years of initial academic appointment (e.g., assistant professor) or is a current postdoctoral fellow
  • Has a research mentor with extensive experience in the field of schizophrenia, bipolar disorder, AUD or OUD
  • Has not received a DP2 award or NIH R01 grant at the time of award, but may be the recipient of a career development (K) award or other mentored research grant
  • Is willing and able to accept funding from a for-profit, biopharmaceutical company
  • Is able to complete the proposed research within 2 years
  • Is a citizen or permanent resident of the United States or holder of a temporary non-immigrant visa that is valid for the duration of the 2-year grant period

Selection Criteria


All applications are reviewed by an independent Review Committee comprising prominent researchers in the relevant field. 

The Review Committee has final responsibility for selection of awardees.

The Review Committee will consider criteria including, but not limited to, overall impact, candidate, mentor, institutional commitment to the applicant and research plan.

Applications are not required to include use of an Alkermes product.    

Application Process & Documents

All applications should be submitted via the Pathways Application Portal.

Apply now    


The following items should be included in the submission:


  1. Completed Application Form
  2. Completed Budget Form
  3. NIH Biosketch of applicant
  4. Letter (1 page) of mentor support
  5. Letter (1 page) from Division Chief or Department Head confirming academic appointment (or postdoctoral fellowship)

An applicant may also submit up to 3 optional supporting documents. All attachments should be added to the application form. Please see below for links to additional guidance and forms.


Pathways guidancePathways application supplementPathways budget form

Additional Information

If you require clarification of any information, please submit an inquiry.


Pathways inquiry form   




Application period opens: Sept. 13, 2021

Application deadline: Nov. 12, 2021 (by 11:59 p.m. ET)

Notification of Review Committee Decision: Q1 2022